Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer enters exclusive global, ex-China licensing pact with 3SBio for development, manufacturing & commercialization of SSGJ-707: New York Tuesday, May 20, 2025, 14:30 Hrs [IST] ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio. 3SBio ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to ...

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading ...

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at ...